GlassScriptPhysician profile
Deborah C Chandler
NPI 1861696247
$60,158.80
in general payments reported to CMS, 2019-2025
33 companies · $4,029 in 2025
The $4,029 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28K · 2022: $4,330 · 2023: $20K · 2024: $3,948 · 2025: $4,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $4,722 · Travel and Lodging: $4,345 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,830.00 |
| Food and Beverage | $4,721.69 |
| Travel and Lodging | $4,344.50 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $46,413.56 | 2021-2025 | Mavenclad, Mavenclad |
| Genzyme Corporation | $4,142.51 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $3,374.73 | 2021-2022 | |
| Genentech USA, INC. | $810.22 | 2021-2023 | Ocrevus |
| Biogen, INC. | $810.15 | 2021-2025 | Tysabri, Vumerity, Aduhelm |
| Celgene Corporation | $630.02 | 2021-2025 | Zeposia |
| Eisai INC. | $550.83 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $523.42 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $422.00 | 2021-2024 | Soliris, Ultomiris |
| Abbvie INC. | $365.29 | 2021-2024 | |
| Horizon Therapeutics Plc | $340.09 | 2021-2023 | Uplizna, Tepezza |
| Lilly USA, LLC | $338.96 | 2021-2024 | Kisunla, Amyvid, Emgality |
| Amgen INC. | $282.66 | 2022-2025 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $196.27 | 2023-2024 | Zeposia |
| Tanabe Pharma America, INC. | $160.41 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $127.42 | 2023 | Mitraclip |
| Banner Life Sciences, LLC | $125.83 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $80.06 | 2023-2024 | Rexulti, Nuedexta |
| Biohaven Pharmaceuticals, INC. | $78.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $72.44 | 2021 | |
| Avanir Pharmaceuticals, INC. | $47.54 | 2021-2022 | |
| Heron Therapeutics, INC. | $46.49 | 2024 | Aponvie |
| Cala Health, INC. | $39.32 | 2025 | Cala Kiq |
| Ucb, INC. | $21.10 | 2023 | |
| Boston Scientific Corporation | $20.44 | 2022 | |
| Tg Therapeutics, INC. | $20.22 | 2023 | |
| Lundbeck LLC | $19.44 | 2024 | Rexulti |
| Ani Pharmaceuticals, INC. | $17.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.61 | 2021 | |
| Allergan, INC. | $16.39 | 2021 | |
| Argenx US, INC. | $16.30 | 2024 | Vyvgart Hytrulo |
| Mallinckrodt Hospital Products INC. | $15.61 | 2024 | Acthar |
| Pfizer INC. | $15.49 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Chandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.